Home

Wave Life Sciences Ltd. - Ordinary Shares (WVE)

6.7900
-0.1700 (-2.44%)
NASDAQ · Last Trade: Sep 19th, 3:28 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close6.960
Open6.990
Bid6.780
Ask6.790
Day's Range6.770 - 7.080
52 Week Range5.280 - 16.74
Volume959,929
Market Cap672.10M
PE Ratio (TTM)-8.487
EPS (TTM)-0.8
Dividend & YieldN/A (N/A)
1 Month Average Volume2,217,995

Chart

About Wave Life Sciences Ltd. - Ordinary Shares (WVE)

Wave Life Sciences is a biotechnology company focused on developing innovative therapies for genetic diseases, particularly those associated with inherited disorders. The company specializes in its proprietary approaches to RNA modulation, aiming to address the underlying causes of genetic conditions through precise and targeted treatments. Wave Life Sciences leverages its advanced technology platform to design and develop a new class of therapeutics that hold the potential to improve outcomes for patients with unmet medical needs while conducting research and clinical trials to evaluate the safety and efficacy of its product candidates. Read More

News & Press Releases

Wave Life Sciences Announces Virtual Research Day on October 29th and Participation at Upcoming Investor Conferences
CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that it will host a virtual Research Day on Wednesday, October 29, 2025 at 10:00 a.m. ET. In addition, members of Wave’s management team are scheduled to participate in several upcoming investor conferences. Details are as follows:
By Wave Life Sciences USA, Inc. · Via GlobeNewswire · September 18, 2025
Peering Into WAVE Life Sciences's Recent Short Interestbenzinga.com
Via Benzinga · September 12, 2025
Top movers analysis one hour before the close of the markets on 2025-09-03: top gainers and losers in today's session.chartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · September 3, 2025
Wave Life Sciences Tumbled 19% Today, But Not Everyone’s Disappointed – Find Out Whystocktwits.com
Via Stocktwits · September 3, 2025
Earnings Scheduled For July 30, 2025benzinga.com
Via Benzinga · July 30, 2025
Insights into WAVE Life Sciences's Upcoming Earningsbenzinga.com
Via Benzinga · July 29, 2025
Forecasting The Future: 7 Analyst Projections For WAVE Life Sciencesbenzinga.com
Via Benzinga · September 3, 2025
Why Is GSK Partner Wave Life Sciences Stock Trading Lower On Wednesday?benzinga.com
Wave Life Sciences shares early WVE-006 trial results in alpha-1 antitrypsin deficiency, reporting durable protein production and favorable safety.
Via Benzinga · September 3, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · September 3, 2025
Crude Oil Falls Over 2%; Campbell's Earnings Top Estimatesbenzinga.com
Via Benzinga · September 3, 2025
Wednesday's session: gap up and gap down stockschartmill.com
Today's session on Wednesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · September 3, 2025
Nasdaq Gains Over 100 Points; Dollar Tree Post Upbeat Earningsbenzinga.com
Via Benzinga · September 3, 2025
Which stocks are moving before the opening bell on Wednesday?chartmill.com
Wondering what's happening in Wednesday's pre-market session? Find an overview in this article.
Via Chartmill · September 3, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · September 3, 2025
Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
Achieved durable production of serum AAT protein at levels associated with a lower risk of AATD liver and lung diseases following repeat 200 mg doses of WVE-006 (11.9 µM total AAT, 7.2 µM M-AAT) 
By Wave Life Sciences USA, Inc. · Via GlobeNewswire · September 3, 2025
This AeroVironment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga.com
Via Benzinga · August 4, 2025
Beyond The Numbers: 6 Analysts Discuss WAVE Life Sciences Stockbenzinga.com
Via Benzinga · August 4, 2025
Wave (WVE) Q2 Revenue Drops 56%fool.com
Via The Motley Fool · July 31, 2025
Wave Life Sciences Ltd (NASDAQ:WVE) Reports Q2 2025 Earnings: Revenue Miss but Narrower Loss and Clinical Progress Boost Shareschartmill.com
Wave Life Sciences Q2 2025 results show $8.7M revenue miss but narrower EPS loss. Stock rises on optimism for WVE-006's AATD clinical progress.
Via Chartmill · July 30, 2025
Wave Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
WVE-006, the leading GalNAc-RNA editing oligonucleotide designed to correct AAT protein and address both lung and liver manifestations of AATD, rapidly advancing in RestorAATion-2 study of AATD patients; multi-dosing is complete in first cohort (200 mg) and single dosing is complete in second cohort (400 mg)
By Wave Life Sciences USA, Inc. · Via GlobeNewswire · July 30, 2025
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mondaybenzinga.com
Via Benzinga · July 28, 2025
Wave Life Sciences Second Quarter 2025 Financial Results Scheduled for July 30, 2025
CAMBRIDGE, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, July 30, 2025, to review the company’s second quarter 2025 financial results and provide business updates.
By Wave Life Sciences USA, Inc. · Via GlobeNewswire · July 23, 2025
Breaking Down WAVE Life Sciences: 4 Analysts Share Their Viewsbenzinga.com
Via Benzinga · July 16, 2025
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · July 10, 2025
Where WAVE Life Sciences Stands With Analystsbenzinga.com
Via Benzinga · June 23, 2025